Verdict
Pakistan Synthetics Limited (PSYL) closed the year ended 30 June 2026 with a materially stronger reported profit despite lower revenue. Gross and operating margins improved, finance costs eased, and the prior year’s large associate loss disappeared. However, the earnings jump overstates the improvement in recurring operations: other income included a dilution gain and a provision remeasurement gain, while operating cash flow fell sharply as inventory rose and capital expenditure remained heavy.
The result is therefore constructive but mixed. The core manufacturing business absorbed a 7.2% sales decline and still delivered higher gross profit, which is a real improvement. Yet free cash flow was negative, total borrowings increased by about 28%, and the dividend remained nil. The next phase must convert the stronger income statement into cash without relying on further balance-sheet expansion or non-recurring gains.
Results at a glance
All financial figures below are from the audited consolidated accounts and are stated in PKR million unless noted otherwise.
Revenue fell 7.2% to PKR 15,666.2 million from PKR 16,872.3 million. Gross profit nevertheless rose 3.0% to PKR 2,036.1 million, lifting gross margin to 13.0% from 11.7%, an improvement of about 129 basis points.
Reported operating profit increased 11.7% to PKR 1,649.5 million from PKR 1,477.1 million. The operating margin expanded to 10.5% from 8.8%. Profit before tax and levy more than doubled to PKR 1,389.1 million, while profit after tax rose 120.8% to PKR 811.4 million. Earnings per share increased to PKR 5.85 from PKR 2.65.
The board did not recommend a dividend. Management said profits were retained to meet long-term commitments, a decision consistent with the year’s large capital programme and higher borrowing requirement.
What improved
Margins strengthened despite lower sales
The most encouraging part of the result is that gross profit rose even though revenue declined. Raw and packing-material consumption fell 5.5% to PKR 10,587.9 million, wages declined 11.1% to PKR 430.5 million, and stores and spares fell 6.4% to PKR 523.6 million. Fuel and power, however, edged up 1.6% to PKR 998.0 million, while depreciation increased 18.4% to PKR 530.1 million after continued investment in production assets.
This arithmetic explains the margin gain: the reduction in material and labour costs outweighed higher power and depreciation charges. The filing does not quantify the split between price, product mix and volume, so it would be speculative to assign the improvement to any one of those drivers. What is demonstrable is that cost of sales fell faster than revenue.
Operating overheads were better controlled
Administrative expenses declined 10.9% to PKR 231.5 million and distribution expenses fell 42.8% to PKR 69.9 million. PSYL also recorded a PKR 17.7 million reversal of expected credit losses, compared with a PKR 13.7 million charge a year earlier. These items supported the rise in reported operating profit and broadened the improvement beyond gross margin alone.
Finance costs fell as rates eased
Total finance costs declined 9.3% to PKR 602.8 million. Finance expense on short-term borrowings fell to PKR 460.8 million from PKR 568.9 million, more than offsetting the rise in long-term borrowing costs to PKR 122.0 million from PKR 77.3 million. That pattern is consistent with Pakistan’s lower lending-rate environment during FY2026: the State Bank reported that weighted-average lending rates had fallen to 12.0% by December 2025 from above 20% in June 2024.
Why reported profit rose so much
The 121% increase in net profit came from both operating progress and a favourable swing below operating profit. Other income jumped to PKR 342.3 million from PKR 29.8 million. It included a PKR 120.7 million gain after PSYL’s interest in Petpak Films Limited was diluted from 18.24% to 14.08%, a PKR 138.2 million gain from remeasuring a provision related to SIDC, PKR 34.9 million of investment gains and PKR 12.9 million of dividend income.
At the same time, the share of results from associates moved to a small PKR 0.2 million profit from a PKR 204.5 million loss. Petpak Films itself returned to profit, but PSYL’s recognized share for the year was minimal because of the investment accounting and dilution. Together, the disappearance of the prior associate loss and the unusual gains explain a large part of the jump from operating profit to pre-tax profit.
These gains are valid reported earnings, but they should not be treated as a dependable annual run-rate. A cleaner reading is that recurring operations improved moderately—gross profit rose 3.0% and operating profit 11.7%—while non-operating items amplified the final result.
The tax and levy charge increased to PKR 577.7 million from PKR 270.0 million. That equates to about 41.6% of profit before tax and levy, close to the prior year’s 42.4%. The FY2026 charge included PKR 236.2 million of deferred tax, compared with a PKR 33.9 million deferred-tax credit in FY2025.
Capacity, production and product mix
PSYL expanded its bottle-cap capacity to 648.6 million cartons from 558.6 million. Production rose 5.6% to 571.6 million cartons, but utilization declined to 88.1% from 96.9% because capacity grew faster than output.
Preform capacity increased to 57,400 octabins from 52,000, while production climbed 22.8% to 44,155 octabins. Utilization improved to 76.9% from 69.1%. PET resin capacity remained 28,000 tonnes, but production fell 8.0% to 20,793 tonnes and utilization eased to 74.3% from 80.7%. Management describes production as demand-driven.
The diverging utilization trends matter. Preforms delivered the clearest production growth, bottle caps grew but carried new spare capacity, and PET resin weakened. The accounts do not disclose product-level selling prices, margins or revenue, so the precise contribution of each product to the group’s margin expansion cannot be verified.
What weakened or needs attention
Cash conversion deteriorated
Cash generated from operations fell to PKR 1,224.4 million from PKR 3,423.8 million. After finance costs and taxes, net operating cash flow declined 81.4% to PKR 407.8 million from PKR 2,198.0 million. The principal drag was working capital: inventory absorbed PKR 739.1 million and lower trade and other payables absorbed a further PKR 349.2 million, partly offset by a PKR 69.3 million release from trade receivables.
This is the clearest tension in the result. The income statement strengthened, but the operating cycle consumed cash. Inventory ended the year at PKR 3,712.9 million, 24.9% above the prior year, while revenue was lower. Raw materials and packing materials accounted for much of the build, ending at PKR 2,519.3 million versus PKR 1,581.4 million.
Investment outpaced internally generated cash
Capital expenditure rose 33.5% to PKR 1,287.3 million. Net operating cash flow covered less than one-third of that amount, leaving a sizeable funding gap before other investing flows. Net investing outflow was PKR 1,275.9 million, while financing activities supplied PKR 973.7 million.
The financing inflow included PKR 682.2 million of new long-term borrowing and a PKR 497.1 million increase in short-term borrowings, partly offset by repayments. Total borrowings increased 28.0% to PKR 4,370.2 million from PKR 3,415.6 million. The filing’s gearing measure increased slightly to 44% from 43%.
Equity rose 17.5% to PKR 5,439.0 million, supported by retained earnings, while total assets increased 13.1% to PKR 12,668.4 million. Current assets of PKR 7,250.2 million exceeded current liabilities of PKR 5,651.2 million, implying a current ratio of about 1.28 times versus 1.16 times a year earlier. Even so, year-end cash was only PKR 16.2 million and bank overdrafts pushed cash and cash equivalents to negative PKR 690.5 million.
AlphaGen model scores
The following are AlphaGen model outputs, not figures reported by Pakistan Synthetics or PSX:
- Alpha QoQ Score: 84.69
- TTM Performance Score: 93.32
- 3Y Business Perf Score: 60.25
- Sector Leadership Score: 63.7305
The high quarterly and trailing scores align with the sharp earnings recovery, while the more moderate three-year and sector-leadership readings are consistent with a business that still needs stronger cash conversion, steadier utilization and a lower dependence on financing.
What to monitor next
First, watch whether inventory normalizes. A release of the FY2026 stock build would materially improve operating cash flow; a further build without matching sales growth would increase funding pressure.
Second, assess whether gross margin near 13% can hold once capacity ramps and input prices move. The FY2026 gain is encouraging, but the filing does not provide enough product-level price and mix detail to prove that the entire improvement is structural.
Third, track the funding profile. Lower market rates helped short-term finance costs during FY2026, but year-end debt was higher and long-term interest expense was already rising. The benefit from rates can be diluted if average borrowings continue to expand.
Fourth, separate recurring earnings from investment and accounting gains. Future comparisons should not assume another dilution gain, provision remeasurement gain or equally favourable associate swing.
Finally, monitor utilization after the bottle-cap and preform expansions. Higher throughput without a matching inventory build would be the strongest evidence that the capital programme is translating into durable returns.
Bottom line
PSYL’s FY2026 result shows genuine operating progress: higher gross and operating profit on lower revenue, improved margins, lower overheads and reduced finance costs. But the quality of the profit increase is mixed because non-recurring gains and the reversal of an associate loss magnified the outcome, while cash conversion deteriorated and debt funded a substantial part of the investment programme.
The next annual cycle should be judged less by whether reported profit rises again and more by whether inventory converts into cash, new capacity earns an adequate return, and debt growth slows. Those tests will determine whether FY2026 was the start of a stronger operating phase or mainly a favourable accounting and investment year.
Primary sources
Pakistan Synthetics Limited annual report for the year ended 30 June 2026 (PSX PDF)
Pakistan Synthetics Limited financial-results announcement dated 30 September 2026 (PSX PDF)
Pakistan Synthetics Limited company page on Pakistan Stock Exchange
State Bank of Pakistan Monetary Policy Report, February 2026
Evidence limitation: the audited accounts do not provide product-level selling prices, margins or a full price-volume-mix bridge. This analysis therefore explains the verified financial transmission and does not attribute undisclosed commercial causes. Quarterly cash-flow data is not used; cash-flow analysis refers to the audited full year.